Royce O'Neale (Utah Jazz) with a dunk vs the Sacramento Kings, 04/10/2021
Royce O'Neale (Utah Jazz) with a dunk vs the Sacramento Kings, 04/10/2021
Sara Cox will replace Rylan Clark-Neal to present the BBC's semi-final coverage of the Eurovision Song Contest.
The "Cellulose Fiber Market Research Report by Type (Man-made Cellulose Fibers and Natural Cellulose Fibers), by Application (Apparel, Home Textile, and Industrial) - Global Forecast to 2025 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.
The "Antimicrobial Coatings Market - Global Outlook and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
Walmart said it now expects fiscal 2022 earnings to increase in high single digits, while previously the company had forecast a slight drop in profit for the year. Operating income rose 32.3% to $6.91 billion in the quarter, while adjusted earnings was $1.69 per share.
Walmart, the world's largest retailer, will post quarterly results Tuesday morning, with the report set to show a wave of elevated consumer spending at the retailer in 2020 moderated slightly in the first three months of this year.
The pandemic has impacted our mental health and well-being. Feelings of stress, loneliness and anxiety can often make their way into our workplaces.
MONACO (AP) _ Eneti Inc. (NETI) on Tuesday reported first-quarter net income of $41.9 million, after reporting a loss in the same period a year earlier. On a per-share basis, the company said it had profit of $3.84. Earnings, adjusted for non-recurring gains, were $2.75 per share. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 11 cents per share. The dry bulk ocean shipper posted revenue of $59.8 million in the period. Eneti shares have climbed 20% since the beginning of the year. The stock has increased 39% in the last 12 months. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on NETI at https://www.zacks.com/ap/NETI The Associated Press
REYKJAVIK, Iceland (AP) — On a trip overshadowed by the crisis in the Middle East, U.S. Secretary of State Antony Blinken on Tuesday touted the Biden administration’s abrupt shift in its predecessor’s climate policies as he visited Iceland for talks with senior officials from the world’s Arctic nations. In Reykjavik for a meeting of foreign ministers of the eight members of the Arctic Council, Blinken heralded President Joe Biden’s return to the Paris climate accord and determination to combat climate change. Yet the worsening violence between Israel and the Palestinians hung over the discussions. A small group of pro-Palestinian demonstrators holding banners and flags protested outside the conference center where Blinken met Icelandic Foreign Minister Gudlaugur Thor Thordarson. “We are very focused on reinvigorating our closest alliances and partnerships, and also our engagement in multilateral institutions, and being here really represents both aspects of that effort,” Blinken told the foreign minister. He lauded Iceland for its strong support for human rights, climate change mitigation and the role it plays in NATO. The Arctic is warming faster than the rest of the world and has been particularly hard hit by rising sea levels from melting sea ice and glaciers. Former U.S. President Donald Trump had alienated Arctic countries and others with his dismissal of the phenomenon and his withdrawal from the 2015 Paris agreement. Trump’s former Secretary of State, Mike Pompeo, also stunned many in the environmental community at an Arctic Council meeting two years ago in Finland with a call for countries to embrace and harness climate change, particularly the opening of new sea lanes due to melting ice, for commercial gain. Blinken will tour several Icelandic geo-thermal energy sites later Tuesday before holding a series of bilateral meetings with other Arctic Council foreign ministers on Wednesday. Among them will be Russian Foreign Minister Sergey Lavrov in what will be the highest-level face-to-face talks between the two countries since Biden took office. Blinken will see Lavrov amid a sharp deterioration in ties between Washington and Moscow sparked by Russia's build-up of troops along the border with Ukraine, cyberattacks and allegations that Russia interfered in U.S. presidential elections in 2016 and 2020. The two nations are also at odds over influence in the Arctic, with Russia insisting its large Arctic landmass makes it the pre-eminent power in the region. Moscow and Washington are also embroiled in a bitter dispute over the status of their respective embassies and consulates after tit-for-tat expulsions this year. Russia has given the U.S. until Aug. 1 to get rid of all non-American staff at its diplomatic missions, something the U.S. says will make it nearly impossible for its facilities to function. Blinken and Lavrov's talks will also serve as a preview for an expected summit between Biden and Russian President Vladimir Putin next month. Senior officials say Biden is interested in testing the proposition that the U.S. and Russia can work collaboratively on certain issues, like climate change, the Mideast, Iran and North Korea, despite bitter disagreements on others. ___ Follow all AP stories on climate change issues at https://apnews.com/hub/climate. By Matthew Lee, The Associated Press
Local ponds are anything but basic. Here’s how to catch bass, trout, bluegill and more without straying far from Boise.
Liberty Defense Holdings Ltd. ("Liberty" or the "Company") (TSXV: SCAN) (OTCQB: LDDFF) (FRANKFURT: LD2), a leading concealed weapons detection company, is pleased to announce that it has entered into an agreement with Canaccord Genuity Corp. as lead agent (the "Lead Agent"), on behalf of a syndicate of agents (the "Agents"), in connection with a commercially reasonable best efforts brokered private placement of up to 10,000,000 units of the Company (collectively, the "Units") at a price of C$0.50 per Unit for aggregate gross proceeds of up to C$5,000,000 (the "Offering").
Unconscious bias could be preventing employers from hiring the best staff and improving business performance. A new report from Questionmark, the online assessment provider, argues that leaders should test the skills of workers so that they can make objective decisions on recruitment and promotion.
Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQX: CANSF), a Canadian biotechnology company that manufactures ultra-pure, sustainably produced cannabinoids via yeast-based biosynthesis, announced today that it has been added to "the Cannabis ETF" (NYSE: THCX) ("THCX"), an exchange traded fund trading on NYSE Arca.
Drill highlights at Rozino include:Drill hole RDD-219; 52.9m grading 0.60 g/t gold, including 16.0m grading 0.95 g/t goldDrill hole RDD-223; 42.0m grading 0.73 g/t gold, including 4.0m grading 3.48 g/t goldVancouver, British Columbia--(Newsfile Corp. - May 18, 2021) - Velocity Minerals Ltd. (TSXV: VLC) ("Velocity" or the "Company") provides an update on positive drilling results from the Rozino gold project located in southeastern Bulgaria. Drilling at Rozino continues to discover significant gold ...
MONTREAL, May 18, 2021 (GLOBE NEWSWIRE) -- Preliminary results from a study underway in Montreal shed important light on the extent to which 2 to 17 years-old have had COVID-19 between last October 2020 and this April 2021. As an overall average, 5.8% of participating children were found to have antibodies to SARS-CoV-2, the virus that causes COVID-19. However, the seroprevalence (proportion of children with antibodies in their blood) increased sharply over time. In October and November of 2020, only 3.3% of children had antibodies. By April 2021, in the third wave, 8.9% of the students tested had antibodies. The results of this study are preliminary and have not yet been peer-reviewed. The study which was announced October 20, 2020, named EnCORE, collected finger prick (dried blood spot) samples from 1,632 children and adolescents attending schools and daycares in four neighbourhoods of Montreal: the West Island, Plateau Mont-Royal, Montreal North, and Mercier-Hochelaga Maisonneuve (HOMA). “Our preliminary results show infections in children and adolescents grew faster in the February-April 2021 period,” says project lead Dr. Kate Zinszer, Assistant Professor at l’École de santé publique, Université de Montréal, and researcher at the Centre de recherche en santé publique. “The results also suggest that seroprevalence is higher in neighbourhoods with lower socio-economic indexes and at a greater percentage for racialized residents. That said, our results could also simply reflect the later timing of recruitment this winter and spring in the Hochelaga-Maisonneuve (HOMA) and Montreal-North areas, corresponding to increased transmission via variants during our third wave.” Seroprevalence estimates by neighbourhood suggest that 4.8% of children and teens on the West Island had antibodies to SARS-CoV-2, 5.4% in the Plateau, 6.2% in HOMA, and 7.3% in Montreal-North. The blood samples were taken from 354 children in daycare, 725 children in elementary schools, and 553 students in high schools. Looking at the geographical split, 33% were from Plateau-Mont-Royal, 31% from the West Island, 22% from HOMA, and 15% from Montreal-North. “Interestingly, of the 95 children who tested positive for antibodies with our serology test, 82% had previously tested negative for SARS-CoV-2 or had never been tested for the virus. This means most of the participating children's infections would have gone undetected without this study,” adds Dr. Zinszer. The survey portion of the study also gives insight into vaccine confidence and the mental health repercussions of the pandemic on Montreal children, teens and their parents. “Most of the parents surveyed, 86%, said that they were likely to have their child vaccinated against COVID-19, but the percent is lower among visible minorities,” states Dr. Zinszer. “About a third (33%) of parents who were from visible minorities indicated they would be reticent to vaccinate their children.” When it comes to behaviour and emotional health, surveys filled out by parents suggest 33% of children have had difficulties with emotions, concentration, behaviour, or relationships with other people. In addition, 55% of children have been less physically active, 54% have been spending more time on screens for non-educational purposes, 81% have been spending less in-person time with friends, and 54% are less socially connected. Interestingly, 14% of parents reported their child was more socially connected during the pandemic than she or he had been before COVID hit. “These preliminary results correspond with growing evidence that COVID-19 is affecting poorer neighbourhoods and racialized communities more than others,” says CITF Leadership Group member Dr. Jim Kellner, a pediatric infectious disease consultant and leader of the CITF’s Pediatric Network. “This means that efforts to protect these communities through public health surveillance, safer workplaces, and tailored vaccine distribution need to be scaled up urgently. As well, vaccinating adolescents is the right thing to do, now that we have vaccines that are Health Canada approved for age 12 and up. Although seroprevalence may have reached 9.6% in some neighbourhoods recently, herd immunity is far off. We need to include younger children in vaccination strategies, offering them safe and effective protection from this very serious illness.” Recruitment continues The EnCORE research study is starting its second phase and is calling on all parents and legal guardians with children attending selected schools and daycares to have their children take part. Participation requires a consent form, an online questionnaire, and a home finger prick test. Researchers will inform parents if their child does have antibodies to SARS-CoV-2, although that still does not guarantee immunity against the virus that causes COVID-19. Vaccination is recommended in any case for people who have antibodies to SARS-CoV-2. To participate in the study or see if your child’s school or daycare is participating, please visit the EnCORE website: encorestudy.ca. About the COVID-19 Immunity Task ForceThe Government of Canada established the COVID-19 Immunity Task Force in late April 2020. The Task Force is overseen by a Leadership Group of volunteers that includes leading Canadian scientists and experts from universities and healthcare homes across Canada who are focused on understanding the nature of immunity arising from the novel coronavirus that causes COVID-19. To that end, the CITF is supporting numerous studies to determine the extent of SARS-CoV-2 infection in Canada (in the general population as well as in specific communities and priority populations), understand the nature of immunity following infection, develop improved antibody testing methods, and help monitor the effectiveness and safety of vaccines as they are rolled out across Canada. The Task Force and its Secretariat accordingly work closely with a range of partners, including governments, public health agencies, institutions, health organizations, research teams, other task forces, and engages communities and stakeholders. Most recently, the Task Force has been asked to support vaccine surveillance, effectiveness and safety as part of its overall objective to generate data and ideas that inform interventions aimed at slowing—and ultimately stopping—the spread of SARS-CoV-2 in Canada. For more information visit: www.covid19immunitytaskforce.ca MEDIA CONTACTS COVID-19 Immunity Task Forcemedia@covid19immunitytaskforce.caRebecca BurnsCell: +1.438.871.8763Caroline PhaneufCell: +1.514.444.4532
HOUSTON, May 18, 2021 (GLOBE NEWSWIRE) -- EARLY WARNING REPORT REGARDING THE SHARES OF CENOVUS ENERGY INC. Item 1 – Security and Reporting Issuer. This press release relates to common shares (“Common Shares”) in the capital of Cenovus Energy Inc. (the “Issuer”). The Issuer’s head office address is: 2600, 500 Centre Street S.E.Calgary, Alberta T2G 1A6 Item 2 – Transaction This press release is being filed on behalf of ConocoPhillips Company (the “Acquiror”) and the other parties identified in Item 2.3 of the Acquiror’s Early Warning Report. The address of the Acquiror is: 925 N. Eldridge Pkwy.Houston, Texas 77079U.S.A. On May 5, 2021, the Acquiror entered into a Stock Sale Instruction (the “First Rule 10b5-1 Plan”) with HSBC Securities (USA) Inc. (“HSBC”) that is intended to comply with the requirements of Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended and to be an automatic securities disposition plan in accordance with applicable Canadian securities laws. Pursuant to this First Rule 10b5-1 Plan, the Acquiror directed HSBC to seek to dispose of up to 16,000,000 Common Shares held by the Acquiror. On May 17, 2021, the Acquiror entered into a second Stock Sale Instruction (the “Second Rule 10b5-1 Plan” and together with the First Rule 10b5-1 Plan, the “10b5-1 Plans”) with HSBC that is intended to comply with the requirements of Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. Pursuant to the Second Rule 10b5-1 Plan, the Acquiror directed HSBC to seek to dispose of up to an additional 32,000,000 Common Shares held by the Acquiror upon the termination of the First Rule 10b5-1 Plan. The Acquiror is issuing this press release to announce its entry into the Second Rule 10b5-1 Plan. The Rule 10b5-1 Plans are part of a planned disposition of the Common Shares held by the Acquiror. The Acquiror intends to fully dispose of all Common Shares by the end of 2022. However, subject to market conditions and any restrictions imposed by applicable law and the Rule 10b5-1 Plans, the Acquiror may, at any time or from time to time, cease the disposition of all or part of any Common Shares they hold. The Acquiror previously received 208,000,000 Common Shares pursuant to a Purchase and Sale Agreement dated March 29, 2017 (the “Purchase and Sale Agreement”), among the Acquiror, ConocoPhillips Canada Resources Corp. (“CPCRC”), ConocoPhillips Canada Energy Partnership, ConocoPhillips Western Canada Partnership, ConocoPhillips Canada (BRC) Partnership and ConocoPhillips Canada E&P ULC (each a “Vendor” and collectively, the “Vendors”) and the Issuer, the Issuer acquired certain oil and gas assets from the Vendors (the “Acquisition”) on May 17, 2017 (the “Closing Date”). The Purchase and Sale Agreement provided that as partial consideration for the Acquisition, the Issuer would issue 208,000,000 Common Shares to CPCRC, as agent for the Vendors, or its affiliate nominee (the “Affiliate Nominee”), the Affiliate Nominee to be identified by CPCRC to the Issuer no later than two business days prior to the Closing Date. CPCRC notified the Issuer on May 11, 2017 identifying the Acquiror as the Affiliate Nominee. Item 3 – Interest in Securities of the Reporting Issuer Following completion of the Acquisition, the Acquiror owned 208,000,000 Common Shares which currently represents approximately 10.3% of the issued and outstanding Common Shares, based on the 2,017,461,576 Common Shares that are currently issued and outstanding on an undiluted basis. The Acquiror subsequently disposed of 2,500,000 Common Shares under the First Rule 10b5-1 Plan and currently holds approximately 10.2% of the issued and outstanding Common Shares. This represents a decrease of approximately 0.1% from the Acquiror’s last reported ownership position of 10.3%. Item 4 – Purpose of the Transaction Pursuant to this First Rule 10b5-1 Plan, the Acquiror directed HSBC to seek to dispose of up to 16,000,000 Common Shares held by the Acquiror. On May 17, 2021, the Acquiror entered into the Second Rule 10b5-1 Plan, pursuant to which the Acquiror directed HSBC to seek to dispose of up to an additional 32,000,000 Common Shares held by the Acquiror upon the termination of the First Rule 10b5-1 Plan. The Rule 10b5-1 Plans are part of a planned disposition of the Common Shares held by the Acquiror. The Acquiror intends to fully dispose of all Common Shares by the end of 2022. However, subject to market conditions and any restrictions imposed by applicable law and the Rule 10b5-1 Plans, the Acquiror may, at any time or from time to time, cease the disposition of all or part of any Common Shares they hold. As of the date of this press release, the Acquiror does not have any future intentions which would relate to or result in the occurrence of any of items (a) through (j) below. (a)a corporate transaction, such as a merger, reorganization or liquidation, involving the reporting issuer or any of its subsidiaries; (b)a sale or transfer of a material amount of the assets of the reporting issuer or any of its subsidiaries; (c)a change in the board of directors or management of the reporting issuer, including any plans or intentions to change the number or term of directors or to fill any existing vacancy on the board; (d)a material change in the present capitalization or dividend policy of the reporting issuer; (e)a material change in the reporting issuer’s business or corporate structure; (f)a change in the reporting issuer’s charter, bylaws or similar instruments or another action which might impede the acquisition of control of the reporting issuer by any person or company; (g)a class of securities of the reporting issuer being delisted from, or ceasing to be authorized to be quoted on, a marketplace; (h)the issuer ceasing to be a reporting issuer in any jurisdiction of Canada; (i)a solicitation of proxies from securityholders; (j)an action similar to any of those enumerated above. Item 5 – Change in material fact The Acquiror is issuing this press release to announce its entry into of the Second Rule 10b5-1 Plan, which is a change in material facts regarding its holding of the Common Shares. ContactsMedia Relations John Roper 281-293-1451 firstname.lastname@example.org Investor Relations 281-293-5000 email@example.com
NEW HAMPTON, N.Y., May 18, 2021 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC) Chairman of the Board, Chief Executive Officer, and President Ted Harris and Chief Financial Officer Martin Bengtsson will present at the Stephens Food & Ag Disrupted: Public-Private Conference on May 25, 2021. Balchem’s presentation will begin at 9:00 a.m. (ET). Follow the below link to listen to this presentation https://kvgo.com/stephens-food-ag/balchem-corp-may-2021 About Balchem Corporation Balchem Corporation develops, manufactures and markets specialty ingredients that improve and enhance the health and well-being of life on the planet, providing state-of-the-art solutions and the finest quality products for a range of industries worldwide. The company reports three business segments: Human Nutrition & Health; Animal Nutrition & Health; and Specialty Products. The Human Nutrition & Health segment delivers customized food and beverage ingredient systems, as well as key nutrients into a variety of applications across the food, supplement and pharmaceutical industries. The Animal Nutrition & Health segment manufactures and supplies products to numerous animal health markets. Through Specialty Products, Balchem provides specialty-packaged chemicals for use in healthcare and other industries, and also provides chelated minerals to the micronutrient agricultural market. Contact:Danielle Polanco, Executive and HR Assistant Telephone: 845-326-5600 E-mail: firstname.lastname@example.org
GREENWICH, Conn., May 18, 2021 (GLOBE NEWSWIRE) -- XPO Logistics, Inc. (NYSE: XPO), a leading global provider of transportation and logistics solutions, has deployed an automated solution to manage high-volume reverse logistics for a fashion e-commerce customer in France. The solution integrates multiple technologies, including a state-of-the-art mechanized sortation system, to handle throughput of up to 12 million returned products per year. Returns management is a fast-growing area of outsourced logistics in the e-commerce and omnichannel sectors. XPO customizes solutions to each customer’s requirements; in this instance, eight automated sorting lines for apparel and one line for shoes are integrated with touchless scanner technology. The computerized scanners use machine vision to read color codes instead of bar codes, accelerating the routing of sorted products on conveyors according to condition: ready for inspection, damaged or return to retail. To manage cardboard waste, XPO has deployed an industrial baling press to compact used cartons, reducing environmental impacts and increasing the recycling value. Malcolm Wilson, chief executive officer, XPO Logistics Europe, said, “By automating logistics processes to achieve specific results, our engineering teams make supply chains more efficient and create supportive work environments for our employees. Automation also improves the all-important consumer experience for our e-commerce customers.” About XPO LogisticsXPO Logistics, Inc. (NYSE: XPO) provides cutting-edge supply chain solutions to the most successful companies in the world. The company is the second largest contract logistics provider and the second largest freight broker globally, and a top three less-than-truckload provider in North America. XPO uses a highly integrated network of 1,621 locations in 30 countries to serve more than 50,000 customers. Approximately 140,000 team members, including 108,000 employees and 32,000 temporary workers, help XPO’s customers manage their supply chains most efficiently. The company’s corporate headquarters are in Greenwich, Conn., USA, and its European headquarters are in Lyon, France. Visit xpo.com for more information, and connect with XPO on Facebook, Twitter, LinkedIn, Instagram and YouTube. Media Contacts XPO Logistics, Inc.Joe Checkleremail@example.com XPO Logistics EuropeAnne Lafourcade+33 (0)6 75 22 52 90 firstname.lastname@example.org
BETHLEHEM, Pa., May 18, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests, specimen collection devices, microbiome laboratory and analytical services, today announced that Dr. Stephen S. Tang, President and CEO, will participate in a fireside chat at the UBS Global Healthcare Virtual Conference. The conference will be simultaneously webcast over the Internet. Dr. Tang is scheduled to speak on May 26, 2021, at 2:00 PM EDT. The live webcast and a replay of the presentation can be accessed by going to OraSure Technologies’ web site, www.orasure.com and clicking on the Investor Info link. A replay of the webcast will be available on OraSure Technologies’ web site for 14 days. Alternatively, you can access the live webcast of the presentation here. About OraSure Technologies OraSure Technologies empowers the global community to improve health and wellness by providing access to accurate, essential information. OraSure, together with its wholly-owned subsidiaries, DNA Genotek, Diversigen, and Novosanis, provides its customers with end-to-end solutions that encompass tools, services and diagnostics. The OraSure family of companies is a leader in the development, manufacture, and distribution of rapid diagnostic tests, sample collection and stabilization devices, and molecular services solutions designed to discover and detect critical medical conditions. OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharma, commercial entities and direct to consumers. For more information on OraSure Technologies, please visit www.orasure.com. Company contacts: Scott GleasonSVP of IR and Corp. Communications484email@example.com Jeanne MellVP Corporate Communications484firstname.lastname@example.org
- Partnership between University of Pennsylvania Gene Therapy Program, James Wilson, M.D., Ph.D., Tachi Yamada, M.D., and Temasek - US$200 million financing commitment from Temasek to fund development of next-generation gene therapy companies with Penn’s Gene Therapy Program PHILADELPHIA, May 18, 2021 (GLOBE NEWSWIRE) -- The G2 Bio Companies (G2 Bio Management Company, Inc., and affiliates) launched today with a US$200 million investment commitment from Temasek to accelerate the development of transformative genetic-based therapies. The G2 Bio Companies were founded by the University of Pennsylvania Gene Therapy Program, James Wilson, M.D., Ph.D., Tachi Yamada, M.D. and Temasek, a global investment firm headquartered in Singapore. Dr. Wilson is Director, Gene Therapy Program; Rose H. Weiss Professor and Director, Orphan Disease Center; and Professor of Medicine and Pediatrics, Department of Medicine at the Perelman School of Medicine at the University of Pennsylvania. Dr. Wilson’s laboratory has made seminal contributions to the technology of gene transfer and has paved the way for translation of these technologies into the clinic. He has published over 600 papers and is named on over 200 patents worldwide. “Our mission at the Gene Therapy Program is to discover, translate and greatly accelerate the development and commercialization of life-transformative genetic-based therapeutics. The G2 Bio Companies will leverage the Gene Therapy Program’s capabilities and its deep history in advancing the field of genetic therapeutics to reach more patients in need around the world, including those with more common, non-monogenic diseases,” said Dr. Wilson. Dr. Yamada is a founder of numerous start-up companies, including Phathom Pharmaceuticals and Passage Bio, and has served as Chief Medical and Scientific Officer at Takeda Pharmaceuticals and as Chairman of Research and Development at GlaxoSmithKline. “We formed the G2 Bio Companies to address the unmet needs of patients with the most advanced genetic-based therapies,” said Dr. Yamada. “I am excited to partner with Dr. Wilson and Temasek. Temasek’s history of impactful investments in life sciences and healthcare globally, and unique presence in Asia, ensures they will be a valued partner and long-term collaborator for the G2 Bio Companies.” About the G2 Bio Companies The G2 Bio Companies were founded in 2021 to fund and develop potential next-generation gene therapy candidates from the University of Pennsylvania Gene Therapy Program. The companies are based in Philadelphia, PA. About TemasekTemasek is an investment company with a net portfolio value of S$306 billion (US$214 billion) as of March 31, 2020. Its three roles as an Investor, Institution and Steward, as defined in the Temasek Charter, shape Temasek’s ethos to do well, do right and do good. Temasek actively seeks sustainable solutions to address present and future challenges, through investment and other opportunities that help to bring about a better, smarter and more sustainable world. For more information on Temasek, please visit www.temasek.com.sg. About University of Pennsylvania Gene Therapy ProgramPenn’s Gene Therapy Program manages a portfolio of approximately 50 diseases and dozens of translational research projects using a variety of cutting-edge technologies, including gene therapy, gene editing, and mRNA therapeutic approaches using adeno-associated viruses or lipid nanoparticles. Its nearly 300-person research team engages in drug development research for the treatment of rare or orphan diseases, as well as acquired and pandemic infectious diseases. For further information, please contact: Sarah McCabeStern Investor Relations, Inc.email@example.com 212-362-1200 Aedan LAIPublic Affairs, Temasekaedanlai@temasek.com.sg +65 6828 2465 Financial disclosure: The University of Pennsylvania and Dr. Wilson hold equity interests in the G2 Bio Companies, and will be entitled to receive licensing revenues based on successful technology development and commercialization.
SalMar ASA will hold its annual general meeting on Tuesday 8 June 2021 at 1 pm CET at the company's office in Trondheim. Please find the notice of the Annual General Meeting (AGM) enclosed. To reduce the risk for spread of the coronavirus disease, and in accordance with the recommendations from the authorities, shareholders are asked to not participate physically at the meeting. In stead it is asked that the shareholders exercise their shareholder rights through electronic voting, proxy authorisation form or through the advance voting form. The company published its annual report on 23rd of April 2021. The report is available at the company homepage, www.salmar.no, including other relevant documents for the general meeting. For further information, please contact: Håkon Husby, Head of Investor RelationsTel: +47 936 30 449Email: firstname.lastname@example.org This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Attachment Salmar Notice AGM 2021